Red Cell Genotyping 2014: Clinical Solutions
Red cell genotyping has moved from the bench to the bedside. This Symposium will provide an update on clinical solutions that red cell genotyping provides in transfusion medicine. Clinical and laboratory training aspects are also featured, which accompany the current molecular immunohematology opportunities.
Accurate determination of blood group phenotypes is impossible in the setting of recent transfusion. In addition, clinically relevant phenotype information cannot be determined for patients with autoimmune hemolytic anemias. To address these issues, transfusion medicine laboratories have adopted molecular techniques for clinical application. These techniques are performed using DNA, obtained from white blood cell among other sources, rather than red cells to circumvent the limitations of serologic testing. It is now commonplace to use molecular techniques, which enable to predict blood group phenotypes despite recent transfusion and a positive direct antiglobulin test. In addition, molecular testing can reveal antigen variants that are not obvious with the use of red cell phenotyping, and molecular tests can be designed to evaluate genotypes in the absence of blood group antisera.
Thus, red cell genotyping and the concept of genotype (dry)-matched transfusions provide ‘clinical solutions’ to aid in the reduction of the potential alloimmunizations and transfusion reactions, and to find potential compatible blood where serological testing cannot.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 6 hours of participation for continuing education for allied health professionals.
To Register: visit http://www.bcw.edu/rcg2014 or call 414-937-6271
Physicians’ and scientists involved in blood transfusions
1. Describe the categorization of RhD variants and the resolution of D typing discrepancies that genotyping can provide.
2. Identify red cell genotyping strategies to prevent alloimmunization and transfusion reactions for the chronically transfused patient with Sickle Cell disease.
3. Identify red cell genotyping strategies to prevent alloimmunization and transfusion reactions in patients with warm autoimmune hemolytic anemia.
4. Discuss patient care strategies from examples (vignettes) described during case reviews.
5. Develop an appropriate red cell genotyping teaching and competency program for the transfusion service and immunohematology laboratory staff.
6. Describe the regulatory landscape for red cell genotyping.
Willy Flegel, MD
Blutspendedienst Baden-Wuerttemberg - Hessen
Patents for RHD Genotyping Applications
Jerome Gottschall, MD
NIH Contract – RED III
Susan Johnson, MSTM, MT
Novartis, Grifols, Ortho Clinical Diagnostics
Dan Waxman, MD
Ellen Klapper, MD
Canadian Blood Services
- 6.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 6.00 Hours of ParticipationHours of Participation credit.